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PURPOSE OF REVIEW  
As one of the fastest growing portions of the population, nonagenarians will constitute a 
significant percentage of the stroke patient population in the near future. Nonagenarians are 
nevertheless not specifically targeted by most clinical guidelines. In this review we aimed to 
summarize the available evidence guiding stroke prevention and treatment in this age group. 
RECENT FINDINGS  
Several recent observational studies have shown that the benefits of anticoagulation for the 
oldest old patients with atrial fibrillation may outweigh the bleeding risk.  A sub-analysis of 
the IST-3 trial has shown for the first time that thrombolysis treatment in acute ischaemic 
stroke may be beneficial and safe even in octogenarian patients and older. Several recent 
observational studies have assessed thrombolysis in nonagenarians. The latest of these has 
shown better disability outcomes without increased rates of symptomatic intracerebral 
haemorrhage with thrombolysis. 
 
SUMMARY 
Nonagenarian stroke patients may benefit from similar preventative and therapeutic strategies 
as their younger counterparts. A few important exceptions include primary prevention using 
aspirin or statins. Patient selection is nevertheless essential given the increased adverse event 
rates. Patient preference should play a key role in the decision-making process. Clinical trials 
including more nonagenarian patients are required to yield more robust evidence 
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INTRODUCTION 
In Europe alone, the population older than 90 years is expected to increase from 6.5 to 16.3 
million by 2050 (1). These demographic shifts are expected to be accompanied by concordant 
changes in the epidemiology of chronic diseases (2,3). Cerebrovascular disorders in particular 
exhibit such a pattern: over 20 cases in 1000 patient-years occur over the age of 85 (4), 
accounting for 17% of all strokes (5).  
Stroke in the very old is associated with a poor prognosis: patients older than 80 years are 
twice more likely to die within 30 days, with a 50% increased risk of dependency (4). Those 
older than 85 are 3 times more likely to die at 5 years (6). Whilst these differences may be 
attributable to factors such a decreased life expectancy, high co-morbidity burden or 
decreased compensatory reserve in the very elderly (7,8), evidence suggests that older stroke 
patients may receive poorer care than their younger counterparts (8). Given that the evidence 
for the prevention and management of stroke in the very elderly is scarce (9), clinicians may 
often be reluctant to offer treatments that may be perceived as ‘high-risk’, such as 
anticoagulation for atrial fibrillation or thrombolysis in the setting of acute ischaemic stroke 
(9).  
In this review, we aim to summarise the latest evidence regarding the use of preventative and 
curative therapies in acute stroke patients older than 90 years of age. We also highlight the 
ethical aspects of management in this patient group.  
  
PREVENTION 
The mainstay of stroke primary prevention is the management of modifiable risk factors (10). 
The INTERSTROKE study (11) evaluated the effects of modifiable risk factors on stroke 
incidence in 32 countries and reported that 10 risk factors are implicated in up to 90% of 
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strokes in all ages. These risk factors include hypertension, smoking, cardiovascular disease, 
obesity and dyslipidaemia. Despite extensive literature regarding the management of these 
risk factors and the benefits of treatment (10), there is limited evidence for those over 80 
years of age. The following strategies outline the current evidence in regards to these risk 
factors as applied to nonagenarians. 
Lifestyle Modification  
Physical inactivity has been shown to be associated with a 60% increase in the risk of 
incident stroke in patients older than 80 years (12). Furthermore, the relationship between 
smoking and adverse cardiovascular events has also been confirmed in older adults (13).  
The adoption of an active lifestyle along with a balanced diet and smoking cessation may be 
as effective for the primary prevention of stroke in the oldest old as in the general population 
(5,14). More importantly, such approaches are especially advantageous in the oldest old since 
they do not contribute to increasing polypharmacy. 
 
Hypertension Control 
Hypertension is the most important risk factor for stroke (15). Nevertheless, the management 
of hypertension is more complex in the oldest old patients. The classic paradigm of blood 
pressure control “the lower the better” may not apply to the very elderly and frail, who may 
be predisposed to cognitive dysfunction, hypotension, and falls (16). Furthermore, the issue 
of polypharmacy is vitally important in a population especially vulnerable to the adverse 
effects of pharmacotherapy and drug-drug interactions (17,18). 
A few studies have reported the outcomes of antihypertensive therapy in octogenarians and 
above. A meta-analysis of the INDANA intervention trials (19) showed that blood pressure 
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management reduces the stroke risk by up to 33% in those older than 80. The HYVET trial 
(20) showed that blood pressure reduction using indapamide ± perindopril in octogenarians 
reduced the risk both overall mortality and stroke incidence by 21% and 30%, respectively. It 
is worth noting that the blood pressure target in the HYVET study was 150/80 mmHg, 
slightly higher than those recommended in current guidelines for younger age groups.  
Nevertheless, it is important to note that these studies have limited their evidence base to the 
healthiest and less frail individuals by excluding those with certain co-morbidities and care 
home residents.  
Expert opinion statements regarding the management of hypertension in old and frail patients 
have emphasised that based on currently available evidence, hypertensive patients older than 
80 years of age should be treated to a target systolic blood pressure between 130 and 150 
mmHg (21,22). It has been recommended that therapy should always be initiated as low-dose 
monotherapy only after a frailty assessment (21). 
Dyslipidaemia Control 
Whilst the evidence supporting the use of statins in the primary and secondary prevention of 
cardiovascular and cerebrovascular disease is robust (10), most studies have only provided 
evidence for patients with a mean age of 75 years (23,24). Whilst current guidelines 
recommend the use of statins in all patients irrespective of age, the evidence base is very 
scarce for the very elderly. The largest observational study to date including 8307 patients 
older than 85 years has concluded that statin use was not associated with any benefit in 
incident stroke or death in these patients (25). Data from clinical practice suggest that the 
oldest old patients are nevertheless prescribed statin therapy, albeit less frequently (26).  
Statin use in the very elderly may be associated with myopathy (27), sarcopenia (28) and 
ultimately falls and fractures. Furthermore, it has been suggested that statin use may be 
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associated with an increased risk of incident haemorrhagic stroke in patients with a previous 
transient ischaemic attack or stroke (29,30). Despite the fact that the most recent meta-
analysis have failed to support this claim in either primary or secondary stroke prevention, no 
age-dependent sub-analyses have been performed in these studies (31-34). Given that age 
may play an important role in the statin-associated haemorrhagic stroke risk, further studies 
are required to elucidate this relationship for the oldest old.  
Nevertheless, given the other adverse effects that may be associated with statin use in 
nonagenarians, it would be sensible to suggest thattheir usage should be discouraged in this 
age group. 
 
Antiplatelet agents 
Primary Prevention 
The use of aspirin in the primary prevention of cardiovascular disease remains a common 
practice amongst older people (35,36), despite doubts of whether the risk-benefit ratio of 
aspirin therapy warrants its use (37,38). Given that the aspirin-associated bleeding risk 
increases significantly in older ages (39), this therapy should not be recommended in the very 
old solely for stroke primary prevention.  
Secondary Prevention 
It has been established that patients with stroke or transient ischaemic attack (TIA) have 
better outcomes with low-dose aspirin monotherapy (40). The risk-benefit ratio in older 
patients is likely to be different than in younger populations, given their higher propensity to 
suffer haemorrhagic complications (41). Nevertheless, in the absence of clinical trials 
evaluating this outcome specifically in the oldest old, it has been suggested that the benefits 
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of aspirin secondary stroke prevention may not be age-dependent (42). The adjunctive usage 
of proton pump inhibitors may be associated with a reduction in gastrointestinal haemorrhage 
rates and may potentially lead to more acceptable outcomes (41), but this needs to be 
weighed against increasing polypharmacy. 
Short-term dual antiplatelet therapy (low-dose aspirin and clopidogrel within the first 21 days 
after stroke) has been recently proposed as a better preventative strategy than aspirin 
monotherapy in patients with minor strokes or TIAs (43). The clinical trials focused mainly 
on younger populations, and therefore their findings may not be necessarily applicable to the 
very old. A careful consideration of the risk-benefit ratio should guide the decision-making 
process until further clinical trial evidence emerges for secondary stroke prevention in 
nonagenarian patients. 
Carotid Endarterectomy and Stenting 
The presence of carotid stenosis is a risk factor for the development of ischaemic stroke (44). 
For asymptomatic patients with carotid stenosis, a comprehensive systematic review has 
shown that surgical endarterectomy (CEA) was associated with both lower mortality and 
incident ipsilateral stroke compared with best medical therapy (45). Nevertheless the CEA-
associated morbidity and mortality were also increased compared to medical therapy (45). 
Nevertheless, given that recent advancements in best medical therapy may decrease the risk 
of ipsilateral stroke to levels comparable to CEA, most recent guidelines only offer a Class 
IIa recommendation for CEA in patients a low perioperative risk (10). Thus, given that 
nonagenarian patients are more likely to be at a higher perioperative risk and that the ACST 
trial failed to show a CEA-associated reduction in the stroke risk in the subgroup of patients 
older than 75 years of age (47), it would be advisable that aspirin and statin therapy be 
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employed for stroke prevention in nonagenarian patients with asymptomatic carotid stenosis 
(10).  
In the case of symptomatic moderate-to-severe carotid stenosis, current guidelines 
recommend CEA for secondary stroke prevention, provided that the perioperative risk is less 
than 6% (48). Conflicting reports exist regarding the safety of CEA in patients older than 80 
years. Whilst some reports suggest that CEA was not associated with a higher peri-operative 
risk in the very elderly compared to younger patients (49-53), others draw the opposite 
conclusion (54-57). A recent meta-analysis of randomised trials has concluded that age 
greater than 75 years was not associated with worse CEA outcomes (58). Nevertheless, 
another meta-analysis of observational studies has concluded that despite similar rates of 
adverse cerebrovascular events with CEA between patients older and younger than 80 years, 
the former were at a higher mortality risk (59).  
Carotid Artery Stenting (CAS) is a percutaneous alternative to CEA for carotid 
revascularisation. The studies evaluating the use of CAS versus CEA in the very elderly have 
yielded more homogenous conclusions, suggesting that CAS should be avoided in this age 
group due to the high peri-operative stroke risk (56,58-62).(63) The ongoing CREST-2 trial is 
aiming to compare the outcomes of best medical therapy, CEA and CAS in the management 
of asymptomatic carotid stenosis. Subgroup analyses from CREST-2 will hopefully provide 
evidence on the best management strategy in the very elderly (64). In the meantime, 
appropriate medical therapy should be mainstay of treatment in those patients regardless of 
whether an interventional approach is also considered. Optimal patient selection for carotid 
revascularisation is essential in the very elderly, and adjunctive tools such as frailty scores 
may prove useful for this purpose (65).  
Prevention of stroke in patients with Atrial Fibrillation 
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Oral anticoagulation 
Oral anticoagulation (OAC) is the mainstay of the prevention of atrial fibrillation-related 
stroke (66). Despite being at a higher risk of stroke (67), a significant proportion of older  
patients with atrial fibrillation (up to 60%) are either not routinely anticoagulated (68-74) or 
receive suboptimal therapy compared to younger patients (68). Older patients are more likely 
to have significant contra-indications to anticoagulant therapy or an unacceptably high 
bleeding risk (75). Nevertheless, a review of the treatment regimens of 3378 care home 
residents with atrial fibrillation (mean age 85 years) has shown that only 56% of those who 
were not anticoagulated were deemed to have clear contraindications (76).Whilst the data 
regarding the quality of anticoagulation specifically in patients older than 90 years is scarce, 
those are even less likely to receive OAC (77,78). Less dramatic differences in the quality 
and quantity of anticoagulation between patients older and younger than 80 years have also 
been reported (79,80). 
Whilst the evidence supporting the use of OAC for primary stroke prevention is robust (81), 
very low numbers of nonagenarians are randomised in those clinical trials, leading to an 
important evidence gap in this age group. Nevertheless, several observational studies 
(68,69,69,77,77,82,82,83,83) and two small clinical trials (84,85) suggest that despite 
increased risks of both ischaemic stroke and major haemorrhage in octogenarians and 
nonagenarians with AF, the efficacy of OAC not only remains superior to anti-platelet 
regimens, but also the benefits of OAC may exceed the risks of major haemorrhage. A further 
consideration specific to the elderly patients receiving OAC is the increased falls risk, which 
may potentially increase the bleeding risk. Nevertheless, recent evidence fails to support this 
hypothesis (86,87). Given that a patient receiving vitamin K antagonist (VKA) therapy would 
need to fall 295 times per year to increase their risk of haemorrhage beyond the benefits of 
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stroke prevention, it has been suggested that a high risk of falling in itself should not 
constitute an absolute contraindication for OAC (88). 
Furthermore, the adoption of Direct OACs (DOAC) represents an important milestone in 
stroke prevention in this age group. The lack of monitoring requirements in DOAC treatment 
has led to the more extensive adoption of OAC in very old patient groups, particularly given 
the higher burden of co-morbid dementia and cognitive decline in this group (77,79). Recent 
evidence suggest that DOACs are at least as effective as VKAs, with comparable rates of 
major haemorrhage (89,90). They currently represent a very attractive alternative for OAC in 
nonagenarian patients due to the ease of administration, the decreased incidence of 
intracranial bleeding events, comparable rates of extracranial haemorrhage with certain 
agents, such apixaban, edoxaban and reduced-dose dabigatran (91) and the emergence of 
specific reversal agents (92). Furthermore, in the context of polypharmacy in older patients, 
DOACs may be associated with fewer, but nevertheless not ignorable, drug interactions than 
VKAs (89,93). Nevertheless, certain cautionary points need to be taken in consideration with 
the usage of DOACs in extreme old age. The very high prevalence of renal impairment 
amongst nonagenarians compared to the general population (94) proves particularly 
problematic in the usage of DOACs, since in this very high-risk patient subgroup there has 
not been an observed reduction in the incidence of ischaemic stroke with DOAC use (95). 
Furthermore, DOACs are contra-indicated in AF related to valvular heart disease, the 
incidence of which may be higher in nonagenarian patients (96).  
Despite the scarcity of available evidence regarding the adoption of OAC in nonagenarian 
patients with AF, certain conclusions may be extrapolated from the rather modest body of 
evidence concerning those over 75-80 years. It is sensible to suggest that the benefit derived 
from OAC is not age-dependent and may still exceed the risks of major bleeding even in 
nonagenarians. This should guide the decision to offer OAC in this group, taking into account 
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the individual patient phenotype, such as those determined to be at a high bleeding risk (75), 
or those with clear contraindications to OAC. Magnetic resonance imaging techniques that 
are able to detect the presence of cerebral microbleeds (CMB) as a marker of cerebral 
amyloid angiopathy may be useful in delineating patient groups in whom OAC may be 
associated with an unacceptably high risk of intracranial haemorrhage (97,98). More recently, 
it has been suggested that the presence of five CMBs may represent an adequate threshold for 
identifying such high-risk subgroups amongst ischaemic stroke patients with AF (99). 
Once the decision to offer OAC has been made, a choice of between VKA or DOAC 
regimens should be performed on a case-by-case basis, taking into the account patient 
preference as well as the co-morbid profile. Conditions such as renal impairment, dementia 
and valvular aetiology of AF along with concomitant pharmacotherapy should be considered. 
 
Left Atrial Appendage Closure devices 
Percutaneous left atrial appendage (LAA) closure is an emerging alternative to OAC in 
patients in whom OAC is either contraindicated or the risks of long-term therapy are 
unacceptably high. LAA closure devices have been shown to be non-inferior to VKAs for 
stroke prevention both in the short-term (100-102) and the long-term (103). Recent evidence 
has shown that LAA closure devices may be suitable in patients with advanced renal 
dysfunction for whom OAC would either involve an unacceptable bleeding risk or would not 
be effective (104). Furthermore, AF patients with a very high co-morbidity burden and in 
whom the OAC-related risk reduction of ischaemic stroke may not be satisfactory, the usage 
of LAA closure devices may improve their outcomes (105). Nevertheless, this procedure is 
not without complications, as it is performed under general anaesthesia and requires peri-
procedural anticoagulation as well as long-term post-procedural anti-platelet therapy (106). 
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Other complications include post-implantation leak or thrombosis (106). Despite the current 
lack of specific evidence for LAA closure in the very elderly, such devices seem to be 
amenable to patient phenotypes commonly seen amongst the elderly.  
 
TREATMENT 
Intravenous Thrombolysis 
The adoption of thrombolytic therapy using recombinant tissue-type plasmin activation 
(rtPA) has represented a revolutionary milestone in the acute treatment of ischaemic stroke. 
Nevertheless those agents are only licensed in the European Union for patients younger than 
80 years (107).  The Third International Stroke Trial (IST-3) was the first trial to show that 
intravenous (IV) rtPA treatment is as beneficial and safe in patients older than 80 years as in 
younger patients, having included 1617 patients over the age of 80 (53% of the total number 
randomised) and 209 patients older than 90 years (108,109). Furthermore, IST-3 patients 
older than 80 years who received IV rtPA had a lower 3-year post-stroke mortality than those 
who did not (110).(109) 
A few systematic reviews exist to date evaluating this patient group. The most recent of those 
concluded as part of a subgroup analysis that patients older than 80 years who received IV 
rtPA within 6 hours had similar stroke disability and mortality outcomes as those younger 
than 80 years (111). Nevertheless, the very low proportion of such patients having been 
randomised in the trials included in this review (other than IST-3) led to the IST-3 being the 
primary driver of the results. A further meta-analysis of individual clinical trial patient data 
suggested that IV rtPA ischaemic stroke onset offered a favourable stroke disability outcome 
in both patients older and younger than 80 years (112). Nevertheless, there was no 
improvement in this outcome with IV rtPA in octogenarians if the treatment delay exceeded 
13 
 
3h (112). The other two meta-analyses that were published before the completion of the IST-
3 trial concluded that IV rtPA treatment was associated with overall less favourable outcomes 
in patients over 80 years of age, including higher mortality. Nevertheless, octogenarians did 
not have a higher incidence of symptomatic intracranial haemorrhage events in either reports 
(113,114). Both studies have concluded that the observed poorer outcomes in the over 80 
group may be related to residual confounding. Observational studies have shown that IV rtPA 
was associated with lower post-stroke disability rates in octogenarians(115-121). 
Furthermore, the rates of post-rtPA symptomatic intracerebral haemorrhage (sICH) were 
similar between octogenarians and younger patients (115-118,122-126). Finally, it has been 
suggested that treatment decisions facilitated by Stroke Telemedicine in octogenarian patients 
receiving IV rtPA achieve similar outcomes as cases where a stroke physician is present on-
site (127). 
The evidence concerning rtPA in the oldest old stroke patients is scarce. Given that only 209 
(7%) of the participants randomised in IST-3 were older than 90 years (109), a sub-analysis 
of this age group has not been performed. A prospective study concluded that stroke patients 
older than 85 years experienced worse mortality outcomes compared to younger age groups, 
without a significantly increased rise in the rate of sICH (128). Observational studies have 
shown that amongst patients receiving rtPA, nonagenarians had higher rates of both 
mortality(122,129) and adverse events(129). Other observational studies have assessed the 
outcomes of nonagenarian stroke patients receiving thrombolysis (130-133), but have yielded 
contradicting results. Whilst most of those suggested that nonagenarians did not benefit from 
IV rtPA (131-133), a recent study including concluded that thrombolysis was associated with 
a better disability outcome without a significantly increased rate of sICH in this age group 
(130).   
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Overall, whilst it seems that increasing age is associated with worse mortality outcomes with 
IV rtPA treatment, it may be the case that residual confounders such as the increasing co-
morbidity burden may be responsible for this effect. Unfortunately, the studies assessing the 
outcomes of nonagenarian patients receiving IV rtPA failed to yield a single conclusion 
regarding the benefit – risk balance, unlike in octogenarians. This is most likely due to the 
high risk of bias inherent from the underpowered, retrospective nature of these studies. 
Current evidence suggests that stroke patients older than 80 years should not be refused IV 
thrombolytic treatment based on age alone, although the therapeutic window in this patient 
group may be limited to 3h. Unfortunately, clear recommendations cannot be made for 
nonagenarians at this point. Further clinical trials of IV rtPA including higher proportions of 
nonagenarians are required. 
 
Mechanical thrombectomy 
Mechanical thrombectomy in conjunction with IV rtPA treatment has been shown to be 
associated with better long-term stroke outcomes (134,135). Out of the five clinical trials that 
included patients older than 80 years of age (136-140), four performed subgroup analyses by 
age. Three of them concluded that patients older than 80 years of age derive the same benefit 
in terms of 90-day disability from mechanical thrombectomy as younger patients 
(136,138,140). This has been further confirmed by a subgroup analysis in a meta-analysis of 
individual patient data including 5 controlled trials (141). Another meta-analysis of 8 
observational studies including a total of 1711 patients concluded that in patients older than 
80 years of age mechanical thrombectomy was as likely to be associated with recanalization 
as in younger patients, without an elevated risk of sICH. Nevertheless, octogenarians had 
poorer 3 month outcomes (142). 
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Similarly to IV rtPA, the body of evidence evaluating this treatment in nonagenarian patients 
is severely limited. Two retrospective studies exist, including 18 and 19 nonagenarian 
patients with stroke, respectively. Whilst one of them has concluded that the acute outcomes 
do not differ based on the age divide alone (143), the other has suggested that nonagenarian 
patients may have lower rates of recanalization post-thrombectomy(144). The latter therefore 
suggests that certain technical difficulties may exist, such as a more complex vascular 
approach. Nevertheless, given that better patient selection may improve the outcomes of this 
procedure, it would be reasonable to suggest that acute stroke patients should not be denied 
mechanical thrombectomy based on age alone. Other more important factors, such as pre-
stroke functional status, co-morbidity burden and stroke severity should be taken into 
consideration when deciding on a therapeutic route in nonagenarians.  
HAEMORRHAGIC STROKE 
The data regarding the epidemiology, risk factors or outcomes of haemorrhagic strokes in the 
very elderly are extremely limited, with no studies focusing solely on nonagenarians. 
However, it has been shown that the clinical characteristics of intracerebral haemorrhage may 
be significantly different between patients older and younger than 80 years, respectively 
(145-147). Thus, very elderly patients may be more likely to have subcortical haemorrhages, 
higher bleed volumes (146) and intra-ventricular extension (145). Poorer outcomes have also 
been reported in the very elderly (146,147). Despite these suggestions, it is worth noting that 
these results originated from small observational studies and hence may not necessarily be 
generalizable to other populations.  In the absence of more specific and robust evidence, an 
individualised approach with reasonable goals should be adopted. In addition, considering the 
high risks of intracerebral haemorrhage associated with pre-existing CMB (97,98,148), 
patients with CMB evidence on blood-sensitive MRI should be managed more intensively, 
focusing particularly on primary and secondary prevention. 
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ETHICAL CONSIDERATIONS 
Besides the medical aspects of stroke treatment in nonagenarian patients, certain ethical 
elements require consideration.  Regardless of age, clinical decisions should be in line with 
the four ethical principles governing medical practice, namely, respect for autonomy, 
nonmaleficence, beneficence, and justice. In terms of beneficence, the growing body of 
evidence evaluating the management of stroke in nonagenarian patients is likely to lead to an 
increase in the available therapies for this age group. Clinicians should be aware of such 
advances and not refuse treatment inappropriately. It is also essential that clinical practice 
minimise iatrogenic harm: high-risk subgroups should be identified through prognostic 
research and caution should be exerted whenever the risk-benefit ratio may not be favourable. 
It is also essential to respect the wishes of the patient and ensure that the necessary 
information about the risk and expected outcomes of non-treatment have been appropriately 
communicated. Nevertheless, given the nature of cerebrovascular events and the relatively 
high prevalence of dementia and cognitive impairment amongst the oldest old, 
communication may not be straightforward. Many nonagenarian patients presenting with a 
cerebrovascular event may not have the capacity to take such a complex decision. Thus, in 
the view of a rapidly growing nonagenarian population, healthcare providers should 
encourage their elderly patients to prepare for such unfortunate eventualities by completing 
Advanced Directives. 
Finally, in a very rapidly ageing population with an increasing co-morbidity burden, 
the healthcare resources that need to be allocated to the prevention and treatment of 
cerebrovascular disease will also increase. According to a recent study in the United 
Kingdom (149), the cost of combined health and social care for stroke sufferers older than 90 
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years of age over 5 years after the index event varied sharply with stroke severity and was 
significantly higher than in younger ages. Thus, the estimated cost for a nonagenarian patient 
with a severe stroke would be £75,000 ($100,000), whilst moderate and severe strokes in this 
age group have been estimated to cost approximately £60,000 ($80,000) and £45,000 
($60,000), respectively. Regardless of the estimated life expectancy of nonagenarian patients, 
it is likely that the healthcare costs will vary with stroke severity proportionally. Thus, efforts 
to prevent stroke and minimise the stroke-associated disability may be associated with an 
overall decrease in healthcare expenditure. 
 Thus, healthcare providers will need to plan resource allocation accordingly, 
emphasising on the importance of prompt and effective preventative and treatment strategies 
to minimise disability and promote independence after stroke. It is only by meeting the 
increased demand in acute geriatric care that fairness can be ensured when deciding the 
clinical management of such complex patients. 
 
CONCLUSION  
Given the rapidly growing segment of population over 90 years and the age-dependent 
incidence of cerebrovascular disease, it is reasonable to expect that the number of 
nonagenarian patients suffering a stroke will also increase dramatically in the coming years. 
Despite the relative paucity of studies evaluating stroke prevention and treatment in this 
patient group, recent years have seen a dramatic increase in such trials. In this review, we 
have assessed the relevant literature covering those topics. We have found that some primary 
stroke prevention therapies may still be recommended in nonagenarians, such as 
anticoagulation for patients with AF, careful management of hypertension and lifestyle 
modifications, whilst aspirin and statin therapy have not proven efficacious. In terms of acute 
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management, we have found that intravenous thrombolysis and mechanical thrombectomy 
may be beneficial even in this age group, but at the cost of higher complication rates. Such 
treatments should be prescribed in a carefully selected nonagenarian population, taking into 
account other factors such as patient preference. Further research that is inclusive of this 
population stratum is encouraged to elucidate current gaps in evidence and to provide 
evidence-based recommendations for clinical practice. 
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